MMV-supported projects Research Translational Product development Access Lead optimization Candidate profiling Human volunteers Patient exploratory Patient confirmatory Regulatory review Preclinical Approved/ERP Miniportfolio GSK Miniportfolio Novartis Pantothenates TropIQ/RUMC SAR121 Sanofi P218 Janssen Artefenomel/ Ferroquine Sanofi Dihydroartemisinin- piperaquine dispersible Alfasigma Artemether- lumefantrine Dispersible Novartis Sulfadoxine- pyrimethamine+ amodiaquine dispersible Fosun Pharma 3 1 7 Phenotypic Lead Mitsubishi Tanabe SJ733 backup Kentucky MMV370 MMV371 Janssen M5717 Merck KGaA Ganaplacide / Lumefantrine Novartis Tafenoquine paediatric GSK Artesunate for Injection Fosun Pharma Sulfadoxine- pyrimethamine+ amodiaquine dispersible S Kant 2 Open Source Series University of Sydney Phenotypic Lead Sanofi MMV253 Zydus Cadila Cipargamin Novartis Artesunate for Injection Ipca 3 Rectal artesunate Cipla Purines Celgene Molecular Target UCB DSM265 Takeda Dihydroartemisinin- piperaquine Alfasigma 8 4 Rectal artesunate Strides Pharma GWT1 Eisai DHODH UTSW/ UW/ Monash MMV048 Pyronaridine- artesunate Shin Poong 9 5 Tafenoquine GSK Molecular Target DDU Dundee Phenotypic Lead Merck KGaA-UCT Pyronaridine- artesunate granules Shin Poong 10 5 Azabenzimidazole UNICAMP Intra-muscular Calibr Artesunate- amodiaquine Sanofi 6 MMV support to projects may include financial, in-kind, and advisory activities. Footnotes: Included in MMV portfolio after product approval and/or development. DNDi and partners completed development and registration of ASMQ and ASAQ. │ Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing. │ WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers. │ Paediatric formulation. Artesunate- mefloquine Cipla Brand names 1: Coartem® Dispersible; 2: Artesun®; 3: Larinate® 60mg; 4: Eurartesim®; 5: Pyramax® tablets or granules; 6: ASAQ Winthrop®; 7: SPAQ-COTM; 8: 100mg Artesunate Rectocaps; 9: ArtecapTM; 10: Kozenis/Krintafel (Trademarks owned or licensed by GSK)

Footnotes: MMV-supported projects Target Product Profiles and Target Candidate Profiles MMV has defined Target Product Profiles and Target Candidate Profiles for medicines to support the eradication campaign. Burrows JN et al., New developments in anti‑malarial target candidate and product profiles et al. Malar J (2017) 16:26 updates the previous profiles in Burrows J et al.; Malaria Journal 2013 12:187 Target Product Profiles indicated by bars at the bottom of each compound box Target Candidate Profiles activities for each individual molecule, indicated by symbols added to compounds in the translational or product development portfolio Burrows Burrows et al., 2013 et al., 2017 Asexual blood stages (TCP-1,2) TCP-1 Relapse prevention (TCP-3a) TCP-3 Transmission reduction (TCP-3b) TCP-5,6 Prophylaxis (TCP- 4) TCP-4 3-day cure, artemisinin-based combination therapies Uncomplicated malaria treatments aiming at a new single-exposure radical cure (SERC) TPP-1 Severe malaria treatment / pre-referral intervention Intermittent /seasonal malaria chemoprevention Products targeting prevention of relapse for P. vivax Single-exposure chemoprotection (SEC) TPP-2